Prostate Cancer

Feb 24, 2022

Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at the data cut-off date, December 20, 2021, the PSA50 response rate was 46% in 28 patients with AR T878X/H875Y tumor muta...

Feb 22, 2022

According to the findings of the ARASENS trial (NCT02799602), presented by Bayer at the 2022 ASCO GU, Nubeqa resulted in a 32.5% reduction in the risk of death, with a median follow-up of 43.7 months for darolutamide.  Nubeqa provided a consistent overall survival advantage across predefined subgroups. The med...

Feb 22, 2022

Preliminary findings of Phase I/II dose-expansion study of DS-7300 (a B7-H3 antibody-drug conjugate) in mCRPC patients backed B7-H3 as a potential new target in treatment-resistant prostate cancers (Abstract #87) Immune-checkpoint inhibitors (ICI) have resulted in significant therapeutic advancements in a wide r...

Feb 21, 2022

Delveinsight brings you the comparative analysis on Positive Phase III trial results of PARP inhibitors, Zejula (Niraparib) and Lynparza (Olaparib) in metastatic CRPC patient population. PARP inhibitors are one of the most promising therapeutic classes in the phase III pipeline, based on the demonstrated effecti...

Jan 04, 2022

FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 for treating metastatic castration-resistant prostate cancer (mCRPC). An i...

Dec 28, 2021

Biogen-Eisai's potential Aduhelm sequel drug secured speedy review by FDA Biogen and Eisai’s Alzheimer’s disease treatment-in-waiting, lecanemab, has been secured a fast-track tag by the FDA, setting up a potentially swift path through the regulatory process. The drug is the next in line behind the pair’s app...

Dec 29, 2020

A USD 4.2 Billion Myovant/ Pfizer Deal Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health.  Relugolix is a once-daily, oral gonadotropin-rel...

Jul 01, 2020

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...

Jun 05, 2020

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...

Feb 19, 2019

CRISPR treatment delivers benefits in mice The researchers from Duke University along with drugmaker Sarepta Therapeutics published a report stating that a single change in the genetic system of Duchenne muscular dystrophy (DMD) affected mice, using CRISPR gene editing tool resulted in increasing their life spa...